logo
Featured on 40:     F-15c Crash     Fall Previews!     MDA Show of Strength     Back to School Pix     Weather Discussion    
Watch ABC40 News Live!   (View)

FDA halts Amgen study after teen patient death

WASHINGTON (AP) — Federal health regulators say they have halted Amgen’s studies of its thyroid drug Sensipar after the death of a 14-year-old patient in a company trial.

The Food and Drug Administration says it is gathering information about the death, but has shut down all studies of the drug in children.

Sensipar is approved for adults to treat over-activity of the parathyroid gland. Amgen Inc. had been studying the drug to see whether it works in children.

The FDA says in a statement it is unclear whether Amgen’s drug had a role in the patient’s death, but it is reminding doctors to prescribe it carefully.

The agency says doctors should monitor patients’ calcium levels to make sure they don’t fall to dangerous levels.

Associated Press

WGGB encourages readers to share their thoughts and engage in healthy dialogue about the issues. Comments containing personal attacks, profanity, offensive language or advertising will be removed. Please use the report comment function for any posts you feel should be reviewed. Thank you.

Comments

WGGB encourages readers to share their thoughts and engage in healthy dialogue about the issues. Comments containing personal attacks, profanity, offensive language or advertising will be removed. Please use the report comment function for any posts you feel should be reviewed. Thank you.
blog comments powered by Disqus